Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, guar gum, magnesium stearate, mannitol, microcrystalline cellulose, sucralose, artificial strawberry flavor
Clinical studies show that 6 to 17% of users experience weight loss, especially when combined with a low-calorie diet and exercise
Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists
Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study
What You Need to Know About Semaglutide Semaglutide is a GLP-1 receptor agonist widely prescribed under brand names such as Ozempic and Wegovy
